I have administered a lot of anthracyclines in the past and never encountered an anaphylactic reaction. They mostly occur in monoclonal antibodies such as Rituximab (Lymphomas) or Infliximabs (not for cancer). And if they do happen with Bisantrene, these anaphylactic reactions are easily managed by stopping the infusion, having a bit of rest, and rechallenging with a slower rate.
Also, if Bisantrene does indeed cause a lot of anaphylactic reactions, we would have known it by now because the Israel study will be stopped.
I’d be more worried about extravasations with anthracyclines (e.g. doxorubicin), but this risk will be eliminated if central lines like PICC lines or ports are used.
Just my opinion
Negatives, page-31
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
0.030(2.52%) |
Mkt cap ! $202.7M | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.22 | $1.16 | $78.70K | 66.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 4561 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.19 |
Change
0.030 ( 0.42 %) |
||||
| Open | High | Low | Volume | ||
| $1.19 | $1.22 | $1.16 | 11297 | ||
| Last updated 15.56pm 07/05/2024 ? | |||||
| RAC (ASX) Chart |